scispace - formally typeset
S

Saleh Alshamrani

Researcher at University of Leicester

Publications -  22
Citations -  116

Saleh Alshamrani is an academic researcher from University of Leicester. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications receiving 45 citations. Previous affiliations of Saleh Alshamrani include Najran University.

Papers
More filters
Journal ArticleDOI

Systematic Review on Pathophysiological Complications in Severe COVID-19 among the Non-Vaccinated and Vaccinated Population

TL;DR: Comparing health complication noted in vaccinated and non-vaccinated individuals (COVID-19 infected patients) to identify the association between vaccination and the multiorgan failure based on the data obtained from case studies, research articles, clinical trials/Cohort based studies and review articles published between 2020–2022 is established.
Journal ArticleDOI

Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines

TL;DR: In this paper , an updated review has been developed to understand the involvement of T cells in the infection mechanism, which in turn determines the prognosis of the disease, and also focused on the T cells' exhaustion under certain conditions and how these functional perturbations can be modulated for an effective immune response against SARS-CoV-2.
Journal ArticleDOI

Suspected Adenovirus Causing an Emerging HEPATITIS among Children below 10 Years: A Review

TL;DR: The suspected cause of acute hepatic failure in the United States of America is adenovirus, including its genomic variations, because its pathogenesis and laboratory investigations have been positively linked.
Journal ArticleDOI

Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study

TL;DR: Hemi-Babim and Fenoterol are a beta-2 adrenergic agonist used for the symptomatic treatment of asthma as a bronchodilator and tocolytic and performed well in molecular dynamics simulation studies, providing evidence that the said drugs can work against the MPro and papain-like protease, which are the main drug targets.